Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  American Journal of Clinical Pathology

• Publication date

  2004-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1309/8A2DJFT07NE6EWHEPMID 15272539
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amplification of HSD17B1 and ERBB2 in primary breast cancer

  2003cited by this paper
• Abnormal chromosome 8 copy number in cytological smears from breast carcinomas detected by means of fluorescence in situ hybridization (FISH)

  2003cited by this paper
• Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres

  2003cited by this paper
• Prognostic and predictive value of HER2/neu oncogene in breast cancer

  2002cited by this paper
• Detection of chromosomal aneuploidies and gene copy number changes in fine needle aspirates is a specific, sensitive, and objective genetic test for the diagnosis of breast cancer.

  2002cited by this paper
• HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer.

  2002cited by this paper
• HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.

  2002cited by this paper
• Her‐2/neu Gene Amplification in Low to Moderately Expressing Breast Cancers: Possible Role of Chromosome 17/Her‐2/neu Polysomy

  2001cited by this paper
• The basic biology of HER2.

  2001cited by this paper
• The role of overexpressed HER2 in transformation.

  2001cited by this paper
• Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe.

  2001cited by this paper
• HER2 as a prognostic and predictive marker for breast cancer.

  2001cited by this paper
• HER2--a discussion of testing approaches in the USA.

  2001cited by this paper
• Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization

  2000cited by this paper
• Role of HER2 gene overexpression in breast carcinoma

  2000cited by this paper
• HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With Survival

  2000cited by this paper
• Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

  2000cited by this paper
• Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

  2000cited by this paper
• HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach

  2000cited by this paper
• Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.

  1999cited by this paper
• Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.

  1999cited by this paper
• The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.

  1998cited by this paper
• The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

  1998cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival.

  1997cited by this paper
• Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies.

  1996cited by this paper
• Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

  1996cited by this paper
• Detection of chromosome aneuploidy in breast lesions with fluorescence in situ hybridization: comparison of whole nuclei to thin tissue sections and correlation with flow cytometric DNA analysis.

  1995cited by this paper
• Immunocytochemical staining of c‐erbB‐2 oncogene in fine‐needle aspirates of breast carcinoma: A comparison with tissue sections and other breast cancer prognostic factors

  1994cited by this paper
• Reduction of telomeric length and c‐erbb‐2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters

  1994cited by this paper
• Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

  1993cited by this paper
• C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast.

  1992cited by this paper
• C-erbB-2 protein and neuroendocrine expression in breast carcinomas.

  1991cited by this paper
• pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

  1991cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Mosher case enters final phase.

  1984cited by this paper
• Histological Grading and Prognosis in Breast Cancer

  1957cited by this paper

• HER2 testing: evolution and update for a companion diagnostic assay

  2025cites this paper
• miR-424-5p suppresses the proliferation and immigration of oral squamous cell carcinoma via down-regulation of KDR.

  2024cites this paper
• Establishment of Rapid and Accurate Screening System for Molecular Target Therapy of Osteosarcoma

  2022cites this paper
• HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional Prognostic Value for Gallbladder Carcinoma

  2022cites this paper
• FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene.

  2021cites this paper
• Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors

  2020cites this paper
• Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings

  2020cites this paper
• Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance

  2020cites this paper
• Synergistic interplay between PHF8 and HER2 signaling contributes to breast cancer development and drug resistance

  2019cites this paper
• Introduction and Application of Fine Needle Aspiration Biopsy

  2018cites this paper
• Evaluation of Estrogen and Progesterone Receptors and Her-2 Expression with Grading in the Fine-needle Aspirates of Patients with Breast Carcinoma

  2018cites this paper
• Introduction

  2018cites this paper
• A novel HER2 gene body enhancer contributes to HER2 expression

  2017cites this paper
• Handbook of Practical Fine Needle Aspiration and Small Tissue Biopsies

  2017cites this paper
• Correlation of HER2 gene status assessment by fluorescence in situ hybridization between histological sections and cytological specimens of breast cancer

  2016influential citation
• HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens

  2016cites this paper
• The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer

  2016cites this paper
• Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections

  2016cites this paper
• Divisional role of quantitative HER2 testing in breast cancer

  2015cites this paper
• Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samples.

  2015cites this paper
• Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China

  2015cites this paper
• The Role of Pharmacogenomics in Individualized Medicine

  2015cites this paper
• Improved DNA Extraction Method for Molecular Diagnosis from Smaller numbers of Cells

  2014cites this paper
• Is Liquid-Based Cytology the Magic Bullet for Performing Molecular Techniques?

  2014cites this paper
• Early Biomarkers in Breast Cancer

  2014cites this paper
• Evaluation of Circulating CA15-3 Tumor Marker Among Sudanese Women With Breast Cancer

  2013cites this paper
• Development of an Ammonium Sulfate DNA Extraction Method for Obtaining Amplifiable DNA in a Small Number of Cells and Its Application to Clinical Specimens

  2013influential citation
• Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.

  2013cites this paper
• Quantification of Her-2/Neu gene in breast cancer patients using real time-polymerase chain reaction (Q-PCR) and correlation with immunohistochemistry findings.

  2013influential citation
• Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer

  2013cites this paper
• Ancillary techniques on direct‐smear aspirate slides

  2013cites this paper
• Genome Aberrations in Canine Mammary Carcinomas and Their Detection in Cell-Free Plasma DNA

  2013cites this paper
• Fine-Needle Aspiration Cytology Can Play a Role in Neoadjuvant Chemotherapy in Operable Breast Cancer

  2013cites this paper
• Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas

  2013cites this paper
• Is it necessary to evaluate nuclei in HER2 FISH evaluation?

  2013cites this paper
• mRNA In Situ Hybridization (HistoSonda): A New Diagnostic Tool for HER2-Status in Breast Cancer–A Multicentric Spanish Study

  2012cites this paper
• Genetic and Expression Analysis of HER-2 and EGFR Genes in Salivary Duct Carcinoma: Empirical and Therapeutic Significance

  2010cites this paper
• Population-based incidence of childhood leukaemias and lymphomas in Spain (1993–2002)

  2010cites this paper
• Kit for quantitative determination of HER2 amplification

  2010cites this paper
• Formes pédiatriques rares

  2010cites this paper
• A Negative Feedback Regulatory Loop Associates the Tyrosine Kinase Receptor ERBB2 and the Transcription Factor GATA4 in Breast Cancer Cells

  2009cites this paper
• TITLE : FoxP 3 Functions as a Novel Breast Cancer Suppressor Gene Through Cooperation with NFAT PRINCIPAL INVESTIGATOR :

  2009cites this paper
• The Correlation of Serum HER-2/neu and CA15-3 in Patients with Metastatic Breast Cancer

  2008cites this paper
• Aberrant Expression of β-HCG in Anaplastic Large Cell Lymphoma

  2008cites this paper
• The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination

  2008cites this paper
• Molecular diagnostics in the cytology laboratory: slowly making its way there

  2008cites this paper
• Nasal-type NK/T-cell Lymphoma Presenting as Hemophagocytic Syndrome in an 11-year-old Mexican Boy

  2008cites this paper
• Non‐anaplastic peripheral t‐cell lymphoma in childhood and adolescence: A Children's Oncology Group study

  2008cites this paper
• Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.

  2008cites this paper
• Lower HER‐2/chromosome enumeration probe 17 ratio in cytologic HER‐2 fluorescence in situ hybridization for breast cancers

  2008cites this paper
• Monoplex LightCycler Polymerase Chain Reaction Quantitation of the HER2 Gene for Quality Assurance of HER2/neu Testing by Immunohistochemistry and Fluorescence In Situ Hybridization

  2008cites this paper
• Evaluation of the prognostic value of 2005 St Gallen risk categories for operated breast cancers in Hong Kong.

  2008cites this paper
• A Unique Case of Adolescent CD56-Negative Extranodal NK/T-Cell Lymphoma, Nasal Type

  2008cites this paper
• Entropy and information content of laboratory test results.

  2007cites this paper
• Tissue microarray technology in breast cancer HER2 diagnostics.

  2007cites this paper
• Morphological detection of hormone and growth factor receptors in breast cancer.

  2007cites this paper
• The prognostic significance of determining DNA content in breast cancer by DNA image cytometry: the role of high grade aneuploidy in node negative breast cancer

  2007cites this paper
• Applications of molecular techniques to fine‐needle aspiration biopsy

  2007cites this paper
• FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene.

  2007influential citation
• The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature

  2007cites this paper
• HER2 testing: a review of detection methodologies and their clinical performance

  2007cites this paper
• Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR.

  2007cites this paper
• The importance of prognostic factors in premenopausal women with breast cancer.

  2007cites this paper
• Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system.

  2007cites this paper
• [Reflexion on innovation diffusion factors: the case of Herceptin].

  2007cites this paper
• Specific requirements for translational regulation by a nascent peptide that stalls ribosomes in response to arginine

  2006cites this paper
• A comparison of five methods for extracting DNA from paucicellular clinical samples.

  2006cites this paper
• First--select the target: better choice of adjuvant treatments for breast cancer patients.

  2006cites this paper
• her-2 upstream open reading frame effects on the use of downstream initiation codons.

  2006cites this paper
• NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer

  2006cites this paper
• An Aggressive Extranodal NK-Cell Lymphoma Arising From Indolent NK-Cell Lymphoproliferative Disorder

  2005cites this paper
• Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma

  2005cites this paper
• Biomarkers to Predict Response to Epidermal Growth Factor Receptor Inhibitors

  2005cites this paper
• Breast fine needle aspiration biopsy: prevailing recommendations and contemporary practices.

  2005cites this paper
• CARCINOMA DA MAMA Determinação da Amplificação do HER2 por Hibridação in situ de Fluorescência (FISH)

  2005cites this paper
• Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

  2005cites this paper